- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07941726
Effect of GABAergic Treatments on Cortical Plasticity and Motor Learning Capacity in the Subacute Phase After Stroke (GABAPLAST)
Effect of GABAergic Treatments on Cortical Plasticity and Motor Learning Capacity in the Subacute Phase After Stroke: a Single-case Experimental Study
The GABAPLAST study explores how commonly prescribed GABAergic drugs prescribed during post-stroke rehabilitation affect cortical plasticity and motor learning capacity. Using a multiple-baseline single-case design, the study evaluates the effects of Baclofen, Oxazepam, and Gabapentin in subacute stroke patients according to their clinical indication. Cortical plasticity capacity is measured with transcranial magnetic stimulation and Paired Associative Stimulation (TMS/PAS). The study aims to determine whether these drugs interfere with or preserve brain plasticity during recovery.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Scientific rationale Functional recovery after stroke relies on neuroplasticity, the brain's ability to reorganize neural connections. During the subacute phase, high synaptic plasticity allows efficient motor relearning, but GABAergic inhibition may reduce these mechanisms. Several animal and human studies suggest that increased GABAergic activity limits long-term potentiation of plasticity (LTP-like) and motor learning. Baclofen (GABA-B agonist), Oxazepam (GABA-A agonist), and Gabapentin (GABA modulator) are routinely prescribed to treat spasticity, anxiety, or neuropathic pain after stroke, yet their neurophysiological effects remain unclear. GABAPLAST aims to provide the first controlled experimental evidence of their direct influence on cortical plasticity and implicit motor learning in subacute stroke patients.
Treatment/strategy/procedure and follow up
The study comprises 26 repeated assessment sessions performed five times per week, from Monday to Friday, over approximately six weeks. Each participant will receive one of the following medications according to their clinical indication: oxazepam for anxiety; baclofen for spasticity; gabapentin for neuropathic pain. Each participant will undergo two consecutive phases:
- Phase A: baseline phase without exposure to the study medication;
- Phase B: phase with exposure to the study medication, including dose titration and treatment at the clinically appropriate dose.
The duration of Phase A will be randomized to 6, 9 or 12 repeated assessments. Phase B will comprise 20, 17 or 14 assessments, respectively, so that each participant completes a total of 26 assessments.
During Phase A, participants in the oxazepam SCED may receive appropriate non-pharmacological usual-care interventions, such as psychological support, relaxation techniques, sophrology or psychotherapy, according to their clinical needs. If immediate pharmacological treatment becomes necessary, the participant will discontinue the study and receive the appropriate treatment without delay.
Medication doses will be adjusted by the investigator according to usual clinical practice, treatment efficacy and tolerability, within the limits defined in the relevant Summary of Product Characteristics and the dose-titration schedules specified in the protocol. Dose changes, dates and reasons for adjustment will be documented in the electronic case report form.
Each assessment session will include: tablet-based motor learning tasks: the Serial Reaction Time Task and Target Jump Task; TMS/PAS assessment of cortical excitability and plasticity; standardized collection of adverse events.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Emmeline Montané, MD
- Номер телефона: +33 05 61 77 90 02
- Электронная почта: montane.e@chu-toulouse.fr
Места учебы
-
-
-
Toulouse, Франция, 31 059
- Raymonde Fournet Purpan Hospital - Toulouse University Hospital
-
Контакт:
- Emmeline Montané, MD
- Номер телефона: +33 05 61 77 90 02
- Электронная почта: montane.e@chu-toulouse.fr
-
Главный следователь:
- Emmeline Montané, MD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Adults (≥18 years) with ischemic or hemorrhagic stroke in the subacute phase (2 weeks-6 months)
- Non-urgent clinical indication for oxazepam, baclofen or gabapentin, with the protocol-defined treatment initiation interval considered medically acceptable by the investigator
- PGI-S score of at least 2 for the symptom leading to treatment prescription
- Ability to understand and consent (BDAE score >3)
- Brain MRI available for neuronavigation
- No motor impairment in the non-paretic hand
- Affiliation with a national health insurance system
- Free, informed and written informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any review required by the research).
Exclusion Criteria:
-
Current or recent treatment, within the previous 7 days, with a gabaergic drug of interest (oxazepam, gabapentin, baclofen)
-
Current or recent treatment, within the previous 7 days, with any prohibited treatment (benzodiazepine, Z-drug, morphine, pregabalin, sedative antipsychotic or barbiturate).
-
History of neurological disorders other than stroke, for example: neurodegenerative disease, multiple sclerosis, epilepsy, brain tumour, hydrocephalus.
-
History of severe psychiatric conditions, such as schizophrenia or bipolar disorder
-
Need for immediate initiation of the planned medication
- Oxazepam: severe respiratory failure, untreated sleep apnoea syndrome, severe acute or chronic hepatic impairment, myasthenia gravis, hypersensitivity to oxazepam or any excipient, galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
- Baclofen: hypersensitivity to baclofen or any excipient, wheat allergy, or coeliac disease
- Gabapentin: hypersensitivity to gabapentin or any excipient, galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
-
Presence of a psychoactive substance dependence
-
Pregnancy or breast-feeding
-
Skin disorder in the stimulated hand indicating the placement of electromyographic collection or stimulation electrodes
-
Medical contraindications for the performance of MSDs according to the TMS safety questionnaire
-
Presence of a major peripheral neuromuscular disorder (e.g. severe motor neuropathy) making the interpretation of PEM unreliable.
-
Guardianship, curatorship, safeguarding of justice
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Baclofen SCED
The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, baclofen intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction. |
Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:
|
|
Экспериментальный: Oxazepam SCED
The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, oxazepam intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction. |
Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:
|
|
Экспериментальный: Gabapentin SCED
The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, gabapentin intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction. |
Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Brain plasticity
Временное ограничение: 6 weeks
|
It will be assessed by the change in the amplitude of the motor evoked potential (MEP) induced by a Paired Associative Stimulation (PAS) protocol, expressed as the percentage change between the pre-PAS and post-PAS measurements. The variation represents the degree of brain plasticity induced by the PAS protocol during a session. It will be done during all the assessments of phase A and phase B. |
6 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Cortical excitability: Membrane excitability of neurons in the motor cortex
Временное ограничение: 6 weeks
|
It will be assessed by the Resting Motor Threshold (RMT), defined as the minimum stimulation intensity, expressed as a percentage of the Maximum Stimulator Output (MSO), that elicits at least 5 motor evoked potentials (PEM) ≥ 50 µV in 10 trials. It will be done during each session of phase A and phase B (except on the last day of each phase). |
6 weeks
|
|
Cortical excitability: Changes in cortical membrane excitability induced by the PAS protocol
Временное ограничение: 6 weeks
|
It will be assessed by the change (Δ) in RMT induced by the PAS protocol, expressed as the percentage change between the RMT measured immediately after PAS and the RMT measured before PAS. It will be done during each session of phase A and phase B (except on the last day of each phase). |
6 weeks
|
|
Cortical excitability: Overall response of the corticospinal tract
Временное ограничение: 6 weeks
|
It will be assessed by the PEM amplitude at the RMT, defined as the "peak-to-peak" average (µV) calculated from a series of 20 PEMs recorded at the RMT. It will be done during each session of phase A and phase B (except on the last day of each phase). |
6 weeks
|
|
Cortical excitability: Conduction and functional integrity of corticospinal tracts
Временное ограничение: 6 weeks
|
It will be assessed by the PEM latency at the RMT, defined as the time (ms) between the magnetic pulse and the onset of the muscle response, averaged over 20 trials. It will be done during each session of phase A and phase B (except on the last day of each phase). |
6 weeks
|
|
Motor learning performance: general learning effect assessed by SRTT
Временное ограничение: 6 weeks
|
The general learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence). During the SRTT, the participant must slide their finger from one position to another as quickly as possible, in response to a visual stimulus appearing at one of the four locations on the screen. In the sequenced condition, a sequence of 8 movements is repeated six times per block, while in the random condition, the 48 positions appear in a random order. The blocks follow the same alternation (R-S-S-S-R-S), allowing for the isolation of effects related to the learning of motor sequences. |
6 weeks
|
|
Motor learning performance: specific learning effect assessed by SRTT
Временное ограничение: 6 weeks
|
The specific learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence). |
6 weeks
|
|
Motor learning performance: retention assessed by SRTT
Временное ограничение: 6 weeks
|
The retention will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random). |
6 weeks
|
|
Motor learning performance: general learning effect assessed by Target Jump tasks
Временное ограничение: 6 weeks
|
The general learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence). During the Target Jumps tasks, the participant must return their finger to the lower center of the screen before each trial, then slide it toward the target that appears. The target shifts a few centimeters as the participant begins the movement. The blocks alternate according to the pattern R-S-S-S-R-S, with random or systematic shifts, allowing for the exploration of visuomotor adaptation abilities. |
6 weeks
|
|
Motor learning performance: specific learning effect assessed by Target Jump tasks
Временное ограничение: 6 weeks
|
The specific learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence). |
6 weeks
|
|
Motor learning performance: retention assessed by Target Jump tasks
Временное ограничение: 6 weeks
|
The retention will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random). |
6 weeks
|
|
Severity of the symptom that lead to initial treatment prescription
Временное ограничение: 6 weeks
|
It will be reported by the patient using the Patient Global Impression of Severity PGI-S completed at inclusion, on the last day of phase A and last day of phase B. This scale ranges from 1 ("no discomfort/pain/anxiety") to 4 ("severe"). Each patient will complete only one PGI-S form, corresponding to the symptom being treated by the study drug. |
6 weeks
|
|
Safety of participants
Временное ограничение: 6 weeks
|
It will be assessed by the spontaneous report on adverse events, assessed at each session. |
6 weeks
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Emmeline Montané, MD, University Hospital, Toulouse
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Боль
- Неврологические проявления
- Заболевания опорно-двигательного аппарата
- Цереброваскулярные расстройства
- Заболевания головного мозга
- Заболевания центральной нервной системы
- Заболевания нервной системы
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Мышечные заболевания
- Мышечный гипертонус
- Нервно-мышечные проявления
- Психические расстройства
- Нервно-мышечные заболевания
- Заболевания периферической нервной системы
- Патологические состояния, признаки и симптомы
- Признаки и симптомы
- Мышечная спастичность
- Инсульт
- Тревожные расстройства
- Невралгия
- Аминокислоты, пептиды и белки
- Органические химические вещества
- Гетероциклические соединения
- Гетероциклические соединения, 2-кольцо
- Гетероциклические соединения, слитое кольцо
- Углеводороды
- Циклогексаны
- Циклопарафины
- Углеводороды, алициклический
- Углеводороды, циклические
- Кислоты, ациклические
- Карбоновые кислоты
- Амины
- Аминокислоты
- Бензазепины
- Гамма-аминобутирическая кислота
- Аминобутираты
- Бутират
- Кислоты, карбоциклический
- Бензодиазепины
- Циклогексанекарбоновые кислоты
- Бензодиазепиноны
- Габапентин
- Баклофен
- Oxazepam
Другие идентификационные номера исследования
- RC31/25/0619
- 2026-526884-39-00 (Другой идентификатор: EU-CT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .